Exagen Company Leadership
XGN Stock | USD 4.05 0.05 1.22% |
About 66 percent of all Exagen's insiders are acquiring. The analysis of the overall insider sentiment regarding Exagen Inc suggests that quite a few insiders are confidant. Exagen employs about 174 people. The company is managed by 11 executives with a total tenure of roughly 406 years, averaging almost 36.0 years of service per executive, having 15.82 employees per reported executive.
Exagen's Insider Buying Vs Selling
66
Selling | Buying |
Latest Trades
2024-11-14 | John Aballi | Acquired 24305 @ 2.81 | View | ||
2024-05-16 | John Aballi | Acquired 40401 @ 1.92 | View | ||
2024-03-04 | Kamal Adawi | Disposed 12784 @ 1.91 | View |
Monitoring Exagen's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Exagen |
Exagen's Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Exagen's future performance. Based on our forecasts, it is anticipated that Exagen will maintain a workforce of about 170 employees by December 2024.Exagen Management Team Effectiveness
The company has Return on Asset of (0.1741) % which means that on every $100 spent on assets, it lost $0.1741. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6997) %, meaning that it generated no profit with money invested by stockholders. Exagen's management efficiency ratios could be used to measure how well Exagen manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.44. In addition to that, Return On Capital Employed is likely to drop to -0.53. At this time, Exagen's Non Current Assets Total are very stable compared to the past year. As of the 26th of November 2024, Intangible Assets is likely to grow to about 6.6 M, while Total Assets are likely to drop about 54.2 M.As of the 26th of November 2024, Common Stock Shares Outstanding is likely to grow to about 18.6 M, though Net Loss is likely to grow to (40.5 M).
Exagen Workforce Comparison
Exagen Inc is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 8,764. Exagen claims roughly 174 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Net Profit Margin of (0.31) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.17) %, which entails that for every $100 of revenue, it lost $0.17. Exagen Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Exagen insiders, such as employees or executives, is commonly permitted as long as it does not rely on Exagen's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Exagen insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-03-01 | 1.0 | 3 | 3 | 259,804 | 19,522 |
2023-03-01 | 0.5 | 2 | 4 | 200,000 | 18,976 |
2022-03-01 | 1.0 | 4 | 4 | 252,000 | 14,045 |
2021-09-01 | 0.5 | 2 | 4 | 16,000 | 15,000 |
2021-06-01 | 2.0 | 8 | 4 | 70,934 | 26,934 |
2021-03-01 | 0.3 | 6 | 20 | 190,000 | 355,496 |
2020-12-01 | 0.0909 | 1 | 11 | 15,000 | 177,947 |
2020-06-01 | 1.1111 | 10 | 9 | 72,470 | 157,365 |
2020-03-01 | 1.0 | 5 | 5 | 332,192 | 333,431 |
2019-09-01 | 0.561 | 23 | 41 | 9,781,338 | 1,039,164,648 |
Exagen Notable Stakeholders
An Exagen stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Exagen often face trade-offs trying to please all of them. Exagen's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Exagen's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
John Aballi | President, CEO | Profile | |
Tina Nova | Executive Directors | Profile | |
Jeffrey Black | Chief Officer | Profile | |
Debra Zack | Chief Officer | Profile | |
John Wegener | Senior Marketing | Profile | |
Ryan Douglas | Investors Officer | Profile | |
Mark Hazeltine | Chief Officer | Profile | |
MingChou Lee | Chief Officer | Profile | |
Michael MD | Chief Officer | Profile | |
MD FACR | Chief Board | Profile | |
MBA MS | Corporate Secretary | Profile |
About Exagen Management Performance
The success or failure of an entity such as Exagen Inc often depends on how effective the management is. Exagen management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Exagen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Exagen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.42) | (0.44) | |
Return On Capital Employed | (0.51) | (0.53) | |
Return On Assets | (0.42) | (0.44) | |
Return On Equity | (1.04) | (1.10) |
Exagen Workforce Analysis
Traditionally, organizations such as Exagen use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Exagen within its industry.Exagen Manpower Efficiency
Return on Exagen Manpower
Revenue Per Employee | 302K | |
Revenue Per Executive | 4.8M | |
Net Loss Per Employee | 136.1K | |
Net Loss Per Executive | 2.2M | |
Working Capital Per Employee | 206.5K | |
Working Capital Per Executive | 3.3M |
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Exagen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Exagen. If investors know Exagen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Exagen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.94) | Revenue Per Share 3.163 | Quarterly Revenue Growth 0.066 | Return On Assets (0.17) | Return On Equity (0.70) |
The market value of Exagen Inc is measured differently than its book value, which is the value of Exagen that is recorded on the company's balance sheet. Investors also form their own opinion of Exagen's value that differs from its market value or its book value, called intrinsic value, which is Exagen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Exagen's market value can be influenced by many factors that don't directly affect Exagen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Exagen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Exagen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Exagen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.